262. What is the predictive value of sulfomucins for concomitant high-grade dysplasia in Barrett's mucosa?
F. Potet (Paris)

263. What is the significance of ornithine-decarboxylase dosage?
R.E. Sampliner (Tucson)

264. Is there a common reactive epitope between colonic and Barrett's epithelia?
K.M. Das, I. Prasad, S. Garla, P. Amenta (New Brunswick)

265. Are allelic lesions of the p53 gene associated with malignant change?
5. Ramel, K. Thor (Stockholm)

266. What is the value of karyotypic (chromosome 7 or 5) OF EGFR (epidermal growth factor receptor) changes in predicting malignant transformation of Barrett's mucosa?
S.R. Hamilton (Baltimore)

267. Does flow cytometry provide any information about the genomic changes during carcinogenesis in the mucosa in CLE?
M. Robaszkiewicz (Brest)

268. What is the relationship between aneuploidy, dysplasia, and cancer? What is the implication of the finding of aneuploidy on a single occasion in a patient with Barrett's epithelium?
H.S. Garewal (Tucson)

269. Should flow cytometry be considered as a routine investigation in the monitoring of CLE?
AJ. Cameron (Rochester)

270. Is image analysis a viable alternative approach to flow cytometry in assaying nuclear DNA content and pattern?
H.S. Garewal (Tucson)

271. In the light of cost-assessment of the disorder, does the risk of adenocarcinoma justify regular endoscopic monitoring of a patient with Barrett's esophagus?
SJ. Spechler (Boston)